Andrea S. Blevins Primeau, PhD, MBA

Patient-reported outcomes in oncology trials are similar whether the trials have open-label or blinded designs, new research suggests.

Roughly half of hospitals accredited by the ACS-CoC failed to disclose the cost of 5 common cancer surgeries, researchers found.

Inpatient treatment with immune checkpoint inhibitors is associated with poor survival outcomes in patients with advanced cancer.

The optimal sequence of treatment for BRAF-mutant melanoma is nivolumab-ipilimumab followed by dabrafenib-trametinib, a study suggests.

Neoadjuvant plus adjuvant pembrolizumab can prolong event-free survival vs adjuvant pembrolizumab alone in resectable melanoma.

Exposure to low-dose methotrexate is associated with an increased risk of melanoma, according to a meta-analysis of 17 studies.

Race and ethnicity were reported in less than 25% of the trials studied.

Researchers sought to determine the impact of body changes on pediatric patients who undergo treatment for AML.